• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Infect Dis . Predicting progression to severe COVID-19 using the PAINT score

tetano

Editor, Senior Moderator
BMC Infect Dis


. 2022 May 26;22(1):498.
doi: 10.1186/s12879-022-07466-4.
Predicting progression to severe COVID-19 using the PAINT score


Ming Wang[SUP] #[/SUP][SUP] 1 2 [/SUP], Dongbo Wu[SUP] #[/SUP][SUP] 1 2 [/SUP], Chang-Hai Liu[SUP] #[/SUP][SUP] 1 [/SUP], Yan Li[SUP] 3 [/SUP], Jianghong Hu[SUP] 4 [/SUP], Wei Wang[SUP] 2 5 [/SUP], Wei Jiang[SUP] 1 [/SUP], Qifan Zhang[SUP] 6 [/SUP], Zhixin Huang[SUP] 6 [/SUP], Lang Bai[SUP] 7 8 [/SUP], Hong Tang[SUP] 9 [/SUP]



Affiliations

Abstract

Objectives: One of the major challenges in treating patients with coronavirus disease 2019 (COVID-19) is predicting the severity of disease. We aimed to develop a new score for predicting progression from mild/moderate to severe COVID-19.
Methods: A total of 239 hospitalized patients with COVID-19 from two medical centers in China between February 6 and April 6, 2020 were retrospectively included. The prognostic abilities of variables, including clinical data and laboratory findings from the electronic medical records of each hospital, were analysed using the Cox proportional hazards model and Kaplan-Meier methods. A prognostic score was developed to predict progression from mild/moderate to severe COVID-19.
Results: Among the 239 patients, 216 (90.38%) patients had mild/moderate disease, and 23 (9.62%) progressed to severe disease. After adjusting for multiple confounding factors, pulmonary disease, age > 75, IgM, CD16[SUP]+[/SUP]/CD56[SUP]+[/SUP] NK cells and aspartate aminotransferase were independent predictors of progression to severe COVID-19. Based on these five factors, a new predictive score (the 'PAINT score') was established and showed a high predictive value (C-index = 0.91, 0.902 ± 0.021, p < 0.001). The PAINT score was validated using a nomogram, bootstrap analysis, calibration curves, decision curves and clinical impact curves, all of which confirmed its high predictive value.
Conclusions: The PAINT score for progression from mild/moderate to severe COVID-19 may be helpful in identifying patients at high risk of progression.

Keywords: COVID-19; NK cell; Prediction; SARS-CoV-2.
 
Back
Top Bottom